BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update [Yahoo! Finance]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance
BioNTech SE BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L1 /VEGF-A bispecific immunomodulator pumitamig with e ight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion , net loss of €1.1 billion (adjusted net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.31 ) (adjusted diluted loss per share of €0.48 ($0.55 Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion Expect 2026 total revenues of €2.0 billion to €2.3 billion, adjusted R&D expenses between €2.2-2.5 billion and adjusted SG&A expenses between €700-800 million BioNTech co-founders Ugur Sahin and Özlem Türeci to establish an independent company with a focus on next-generation mRNA innovation
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech (BNTX) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- BioNTech (BNTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer [Yahoo! Finance]Yahoo! Finance
- BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung CancerGlobeNewswire
- BioNTech (BNTX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.MarketBeat
BNTX
Earnings
- 3/10/26 - Beat
BNTX
Sec Filings
- 3/25/26 - Form 3
- 3/25/26 - Form 3
- 3/25/26 - Form 3
- BNTX's page on the SEC website